News from sorrento therapeutics, inc. A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Jun 20, 2014, 15:15 ET

Sorrento to Present at BIO Business Forum

Sorrento Therapeutics, Inc. (NASDAQ: SRNE) ("Sorrento"), a late-stage clinical oncology company developing new treatments for cancer and its...

Jun 12, 2014, 20:30 ET

Sorrento Announces Underwriters' Exercise of Over-Allotment Option

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE) ("Sorrento" or the "Company"), a late-stage clinical oncology company developing new treatments for...

May 30, 2014, 13:49 ET

Sorrento Therapeutics to Present at Jefferies 2014 Global Healthcare Conference

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento) a late-stage clinical oncology company developing new treatments for cancer and...

May 14, 2014, 23:57 ET

Sorrento Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock

Sorrento Therapeutics, Inc. (NASDAQ: SRNE) ("Sorrento" or the "Company"), a late-stage clinical oncology company developing new treatments for...

May 14, 2014, 16:40 ET

Sorrento Therapeutics, Inc. Announces Proposed Public Offering of Common Stock

Sorrento Therapeutics, Inc. (Nasdaq: SRNE) ("Sorrento" or the "Company"), a late-stage clinical oncology company developing new treatments for...

May 13, 2014, 07:30 ET

Sorrento Announces Transfer of Orphan Drug Designation Sponsorship for Intrathecal Resiniferatoxin from NIH

Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento) a late-stage clinical oncology company developing new treatments for cancer and its associated...

Apr 07, 2014, 15:58 ET

Sorrento appoints Ian Walters as Senior Vice President of Translational Medicine and Corporate Development

Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento) a late-stage clinical oncology company developing new treatments for cancer and its associated...

Apr 04, 2014, 09:43 ET

Sorrento Therapeutics Announces Key Presentation on Cynviloq at the American Association for Cancer Research Annual Meeting

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and its...

Apr 04, 2014, 06:00 ET

Sorrento Announces Presentation of Data from Clinical Study of Resiniferatoxin for Intractable Cancer Pain at ASRA Meeting

Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento) a late-stage clinical oncology company developing new...

Mar 31, 2014, 21:31 ET

Sorrento Announces First Patient Dosed in Registration Trial to Evaluate Bioequivalence Between Cynviloq and Abraxane

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and...

Mar 25, 2014, 07:47 ET

Sorrento Therapeutics Forms Subsidiary Ark Animal Therapeutics to Develop Animal Health Applications

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and...

Mar 11, 2014, 06:00 ET

Sorrento Therapeutics Appoints Mark Durand to its Board of Directors

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and...

Mar 06, 2014, 06:00 ET

Sorrento Therapeutics to Present at ROTH Capital Partners 26th Annual Growth Stock Conference

Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and associated...

Mar 06, 2014, 05:50 ET

Sorrento Therapeutics Announces Three Presentations and a Satellite Symposium on Cynviloq™ at the 31st Annual Miami Breast Cancer Conference

Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and associated...

Mar 03, 2014, 06:00 ET

Sorrento Therapeutics hires Mike Royal as Senior Vice President of Clinical Development

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento) a late-stage clinical oncology company developing new treatments for cancer and...

Feb 11, 2014, 08:00 ET

Sorrento Therapeutics Announces Two Presentations on Cynviloq™ at the Beaujon International Conference on "Cutting Edge in Liver and Pancreatic Tumors"

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and...

Feb 10, 2014, 16:00 ET

Sorrento Therapeutics Expands its Exclusive Rights to Cynviloq™ to Include Australia, Canada and Mexico

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and...

Feb 06, 2014, 08:00 ET

Sorrento Therapeutics to Present at 16th Annual BIO CEO & Investor Conference

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and...

Feb 03, 2014, 06:00 ET

Sorrento Therapeutics Welcomes Daniel Levitt as a Director to its Board

Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento) a late-stage clinical oncology company developing new treatments for cancer and associated...

Jan 10, 2014, 12:50 ET

Sorrento Therapeutics to Present at the Biotech Showcase 2014 and the 7th Annual OneMed Forum SF2014 in San Francisco

Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento; www.sorrentotherapeutics.com) announced today that Dr. Henry Ji, President and Chief Executive...